David and his wife had been trying to conceive for fourteen months before they finally went to see a reproductive endocrinologist together. He’d assumed, honestly, that it was her — assumed this without evidence, without asking, almost reflexively. The news that the issue was his — specifically low sperm count and poor motility, likely from testosterone levels that were both artificially low and somehow simultaneously artificially influenced — took a while to process.
What the doctor explained next was more surprising: the protein supplement he’d been taking for three years, marketed explicitly for men’s health and natural testosterone support, contained compounds suppressing his own testosterone production and potentially impairing his sperm. He’d been actively making the problem worse while trying to be healthy. The label had said nothing about it.
The relationship between testosterone and male fertility is one of the most widely misunderstood topics in men’s health, and the misunderstandings have real consequences — for men trying to have children, and for men trying to optimize their health through testosterone supplementation without realizing the trade-offs they’re actually making.
This article covers the physiology of how testosterone and fertility are linked, what disrupts both, what the evidence says about optimization, and how to think about the specific decisions — supplementation, hormone therapy, lifestyle — that affect both systems at once.
The Hormonal Axis: How Testosterone Production Is Controlled
Understanding testosterone’s relationship to fertility requires understanding the hypothalamic-pituitary-testicular (HPT) axis — the feedback system controlling both testosterone production and sperm production simultaneously. This architecture explains why interventions aimed at raising testosterone can paradoxically impair fertility.
The hypothalamus, a small region at the base of the brain, secretes gonadotropin-releasing hormone (GnRH) in pulses every ninety to one hundred twenty minutes. These GnRH pulses travel to the anterior pituitary gland, stimulating release of two gonadotropin hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH travels through the bloodstream to the testicular Leydig cells, which use cholesterol to synthesize testosterone.
FSH acts on Sertoli cells in the seminiferous tubules, which support the maturation of spermatocytes into mature sperm — a process called spermatogenesis that takes approximately seventy-two days start to finish.
The negative feedback loop is the critical element for fertility. Testosterone (and its conversion to estradiol via aromatase) circulates back to the hypothalamus and pituitary, where it suppresses GnRH and LH secretion. This elegant feedback mechanism keeps testosterone within physiological range. But the same mechanism means that if testosterone is introduced from outside the body — exogenous testosterone — it suppresses LH via feedback, the Leydig cells receive no stimulation signal, and endogenous testosterone production stops cold.
More importantly for fertility, FSH also suppresses, and without FSH-supported Sertoli cell function, spermatogenesis stops too.
This is the core paradox of testosterone therapy and fertility: testosterone replacement therapy reliably normalizes circulating testosterone levels, improving many symptoms of hypogonadism, but it simultaneously impairs or eliminates sperm production by suppressing the pituitary hormones required for testicular function. Studies examining sperm counts in men on testosterone therapy consistently find azoospermia (complete absence of sperm) or near-azoospermia in the majority of treated men.
This is, in fact, the mechanism used in male contraceptive research — testosterone-based hormonal male contraception works through exactly this principle. For men who want children, exogenous testosterone during the fertility window is generally contraindicated.
What Testosterone Actually Does: A Complete Picture
Testosterone is the primary male sex hormone, but calling it “the testosterone” understates the breadth of its physiological effects considerably. Understanding its full scope clarifies what’s actually at stake when levels are suboptimal, and what the genuine goals of optimization should even be.
In reproductive biology, testosterone is essential for the final steps of spermatogenesis — particularly the maturation of spermatids into spermatozoa. Intratesticular testosterone concentrations run roughly 100-fold higher than circulating blood levels, reflecting the seminiferous epithelium’s high testosterone requirement.
Testosterone also drives the development and maintenance of secondary sex characteristics (muscle mass and distribution, bone density, body hair, deepened voice), regulates red blood cell production through stimulation of erythropoietin, influences fat distribution (promoting lean mass and reducing central adiposity), and affects cardiovascular function through multiple mechanisms at once.
In the brain, testosterone — and DHT derived from it, and estradiol derived from it via aromatase — influences libido, mood, cognition, and sleep architecture. The relationship between testosterone and mood runs both ways: low testosterone is associated with depression, irritability, and reduced motivation; depression and chronic stress reduce testosterone through HPA axis effects on gonadotropin secretion. The nervous system effects of testosterone are mediated through androgen receptors in multiple brain regions, including the hypothalamus, hippocampus, amygdala, and prefrontal cortex.
Dihydrotestosterone (DHT), produced locally from testosterone by 5-alpha reductase, is a more potent androgen playing specific roles in prostate and scalp tissue (driving benign prostatic hyperplasia and androgenic alopecia respectively) but also in genital development and sexual function.
Estradiol, produced from testosterone by aromatase in adipose tissue, brain, liver, and bone, plays an important role in male bone health, sexual function, and cardiovascular health — the idea that estrogen is purely a female hormone is simply incorrect, and excessive suppression of estradiol in men (from aromatase inhibitors used to artificially boost testosterone, for instance) impairs bone density, sexual function, and mood.
Testosterone is not a simple masculinity molecule that you either have enough of or you don’t. It’s the hub of an interconnected hormonal network where the downstream products — DHT, estradiol — are as biologically important as testosterone itself. Men who use aromatase inhibitors to prevent estrogen conversion are suppressing a system their bones, brains, and sexual function depend on. The reductive narrative about testosterone optimization misses half the biology.
Male Fertility Basics: What Makes Sperm Good Enough
Male fertility is assessed primarily through semen analysis — but interpreting the results requires understanding what the numbers mean and what influences them. Roughly 40-50% of infertility cases involve a male factor, alone or combined with female factors. Yet men are frequently not evaluated until after an extensive female infertility workup, which delays diagnosis and wastes time and resources that didn’t need to be wasted.
WHO 2021 reference values for semen analysis represent the fifth percentile of fertile men — values below these are considered concerning: volume ≥1.4 mL, total sperm count ≥39 million per ejaculate, sperm concentration ≥16 million/mL, total motility (progressive + non-progressive) ≥42%, progressive motility ≥30%, and normal morphology ≥4% (using strict Kruger criteria). Not ideal values — the lower threshold of what fertile men actually produce.
Men significantly above these values have higher fertility probability; those below carry increased infertility risk but aren’t guaranteed infertile.
Semen analysis alone provides limited diagnostic information. DNA fragmentation testing — assessing the percentage of sperm with DNA strand breaks — provides additional fertility-relevant information standard parameters miss entirely. Men with elevated sperm DNA fragmentation (above 15-25% depending on the assay used) have lower pregnancy rates even with normal concentration and motility, because fragmented DNA impairs embryo development regardless of how well the sperm swim.
Oxidative stress in the reproductive tract is a major driver of DNA fragmentation, and lifestyle factors (smoking, obesity, heat exposure, sedentary behavior) contribute to it significantly.
Genetic causes of male infertility are more common than widely appreciated. Y chromosome microdeletions in the AZF regions (azoospermia factor regions on the Y chromosome’s long arm) show up in roughly 10-15% of men with severe oligospermia or azoospermia. Klinefelter syndrome (47,XXY) affects approximately 1 in 600 males and is the most common chromosomal cause of infertility.
Cystic fibrosis mutations cause bilateral absence of the vas deferens (CBAVD) in men who carry CFTR mutations — a common cause of obstructive azoospermia. These genetic diagnoses carry implications both for treatment options and for genetic counseling before attempting conception.
Causes of Low Testosterone in Men: The Full Spectrum
Primary hypogonadism involves failure at the testicular level — the testes cannot produce adequate testosterone despite adequate LH signaling. Laboratory finding: low testosterone with high LH (the pituitary trying harder because it’s not getting feedback). Causes include Klinefelter syndrome, mumps orchitis (viral damage to Leydig cells), prior chemotherapy or radiation, cryptorchidism (undescended testes), testicular torsion with ischemic damage, and Sertoli cell-only syndrome (where the tubules contain supporting cells but no sperm precursors).
Secondary hypogonadism involves failure at the hypothalamic or pituitary level — the signaling machinery fails to drive testicular function. Laboratory finding: low testosterone with low or inappropriately normal LH and FSH.
Causes include obesity (adipose aromatization of testosterone to estradiol suppresses LH), hypothalamic-pituitary tumors (prolactinomas are the most common, suppressing GnRH through prolactin feedback), hyperprolactinemia from other causes (medications including antipsychotics, dopamine antagonists), chronic opioid use, glucocorticoid excess (Cushing’s syndrome or exogenous steroid use), and congenital causes (Kallmann syndrome — genetic GnRH deficiency with anosmia).
Age-related decline in testosterone — sometimes called “late-onset hypogonadism” — is real but more modest than often represented. Total testosterone declines roughly 1-2% per year after age 30-35. The more important changes happen in free testosterone (biologically active testosterone not bound to SHBG), which declines faster as SHBG (sex hormone binding globulin) rises with age and obesity. By age 70-80, roughly 20-30% of men have total testosterone below 300 ng/dL.
However, symptoms attributable to this decline vary enormously between individuals, and the decision about whether to treat age-related testosterone decline requires careful symptom correlation with laboratory evidence of deficiency — not a number in isolation.
Lifestyle factors that suppress testosterone are underappreciated and often reversible. Sleep deprivation reduces testosterone significantly — a University of Chicago study found sleep restriction to five hours per night for one week reduced testosterone levels by 10-15% in young healthy men. Chronic psychological stress elevates cortisol, which directly suppresses LH secretion and interferes with steroidogenesis. Excessive endurance training — while moderate exercise raises testosterone — can suppress it at extreme volumes through mechanisms similar to chronic stress.
Alcohol chronically suppresses testicular function and reduces testosterone. Obesity reduces testosterone through aromatase-mediated conversion of testosterone to estradiol in fat tissue.
The Testosterone Therapy Decision: Who Benefits and Who Shouldn’t Use It
The landmark TESTOSTERONE TRIALS (TTrials), a coordinated set of seven trials published in NEJM in 2016 and subsequent publications, represent the most rigorous evaluation of TRT benefits in older men with confirmed hypogonadism (testosterone below 275 ng/dL). Results: testosterone treatment significantly improved sexual function, walking distance, bone mineral density, and mood. Results were mixed for cognitive function — minimal benefit there.
The cardiovascular results were concerning in earlier studies (a 2010 NEJM trial was stopped early due to excess cardiovascular events), though the TTrials themselves and larger subsequent studies showed neutral or potentially protective cardiovascular effects in appropriate patients. A 2023 JAMA network analysis found no significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men.
Absolute contraindications to TRT: breast cancer (testosterone can stimulate breast tissue), active prostate cancer (testosterone stimulates androgen receptor-positive prostate cancer), elevated hematocrit above 50-52% (testosterone stimulates erythropoiesis, raising red blood cell count and blood viscosity, increasing thrombosis risk), severe or untreated sleep apnea (testosterone worsens sleep apnea by increasing upper airway fat deposition and altering respiratory drive), and male infertility in men who wish to conceive (it suppresses spermatogenesis).
Delivery methods affect both efficacy and patient experience. Topical gels (testosterone gel 1.62% — AndroGel, Testim, others) are the most commonly prescribed formulation — daily application provides stable hormone levels but requires care to avoid transfer to partners and children through skin contact. Testosterone cypionate or enanthate injections are the most cost-effective option, typically administered every one to two weeks, but produce peaks and troughs in testosterone levels that some men find uncomfortable.
Testosterone pellets (implanted subcutaneously under local anesthesia) provide stable testosterone levels for three to six months. Long-acting injectable undecanoate (Aveed) requires injections every ten weeks in a clinical setting due to REMS program requirements but provides stable levels. Buccal and nasal formulations exist but see less common use.
Preserving Fertility on Testosterone Therapy: Options and Evidence
For men who need testosterone therapy but wish to preserve future fertility — or men who’ve developed hypogonadism symptoms but want to start a family before considering TRT — alternatives to direct testosterone replacement can raise testosterone levels while maintaining or stimulating spermatogenesis at the same time.
Human chorionic gonadotropin (hCG) is a hormone that acts on LH receptors in Leydig cells, stimulating endogenous testosterone production without suppressing FSH.
For men with secondary hypogonadism who want to maintain fertility, hCG injections (typically 500-1,000 IU two to three times per week) can raise testosterone substantially while preserving spermatogenesis, because FSH remains active throughout. hCG is also used in combination with TRT (“co-treatment”) in men already on testosterone who wish to preserve testicular function and spermatogenesis — the combination maintains elevated testosterone while the hCG signal keeps Leydig cells functional and testicular volume intact.
For men with secondary hypogonadism (normal LH/FSH function but inadequate output), selective estrogen receptor modulators (SERMs) including clomiphene citrate and enclomiphene work by blocking estrogen’s negative feedback at the hypothalamus, increasing GnRH and subsequent LH/FSH secretion, and ultimately driving both endogenous testosterone production and spermatogenesis together. This approach is particularly attractive for younger men with secondary hypogonadism who want to maintain fertility — raising testosterone while preserving or enhancing sperm production, rather than sacrificing one for the other.
Studies of clomiphene for male hypogonadism have shown testosterone increases to normal range in the majority of hypogonadal men, with significant improvements in libido, sexual function, and mood symptoms comparable to TRT. Importantly, multiple studies have shown improved or maintained semen parameters on clomiphene — the opposite of what happens with TRT.
The main limitation is that clomiphene also raises estradiol (since more testosterone substrate becomes available for aromatase), which can cause gynecomastia (breast tissue development) in some men and may worsen mood in men sensitive to estrogen fluctuations.
Recovery of spermatogenesis after stopping TRT is possible but not guaranteed. The time required for sperm production to resume varies widely — from three to eighteen months in most cases, with some men recovering fully and others left with permanent suppression, particularly after long-duration high-dose TRT. Men who’ve been on TRT for extended periods and wish to recover fertility may benefit from combination hCG/FSH therapy to accelerate testicular recovery, though response rates are variable and time to recovery unpredictable.
The recovery process should be managed in collaboration with a reproductive urologist or male fertility specialist, not solo.
Optimizing Testosterone and Fertility Naturally: The Evidence Base
Weight loss has the most consistent and dramatic effect on testosterone in overweight men. Adipose tissue contains aromatase that converts testosterone to estradiol, and the magnitude of this conversion scales with fat mass. Studies consistently show 10-20% weight loss in obese hypogonadal men raising total testosterone by 20-40%, with some men moving from frank hypogonadism into the normal range without any pharmacological intervention at all.
A 2012 study in the Journal of Urology found testosterone levels increasing by approximately 2 ng/dL per 1% reduction in body weight in obese men. Weight loss also reduces SHBG over time (SHBG initially rises with weight loss, temporarily reducing free testosterone), and the net effect is typically increased free testosterone and improved hypogonadal symptoms.
Sleep optimization is among the most accessible and underutilized testosterone interventions there is. The University of Chicago study showing 10-15% testosterone reduction with one week of sleep deprivation demonstrates how acutely testosterone responds to sleep quality. Sleep is when roughly 70-80% of daily testosterone secretion occurs, in pulses aligned with slow-wave sleep stages. Men with obstructive sleep apnea have significantly lower testosterone levels that normalize with effective CPAP treatment.
Prioritizing seven to nine hours of sleep per night, treating sleep apnea, and maintaining consistent sleep timing (to support circadian testosterone release patterns) can meaningfully raise testosterone in men with sleep-disrupted baselines.
Exercise for testosterone optimization requires nuance. Resistance training with compound movements (squats, deadlifts, bench press, rows) produces acute testosterone elevations and appears to support baseline levels. However, the chronic testosterone effects of resistance training in men with normal testosterone are modest — perhaps 5-15% at most. For severely hypogonadal men, exercise alone is unlikely to normalize levels on its own.
The benefit is clearest in moderately low-normal testosterone, where lifestyle optimization can be meaningful, and in obese men, where exercise supports the weight loss and body composition changes that produce more substantial testosterone improvements downstream.
For spermatogenesis specifically, heat avoidance is an evidence-based intervention that gets overlooked constantly. Scrotal temperature is normally maintained 2-4°C below core body temperature by the cremaster muscle and pampiniform plexus cooling mechanism. Chronic heat exposure — laptops on lap, prolonged hot tub use, occupational heat exposure, tight underwear — raises scrotal temperature and impairs spermatogenesis.
A randomized study found laptop use on the thighs raised scrotal temperature by 2.6°C after sixty minutes — enough to impair sperm production with chronic exposure. Switching from briefs to boxers, avoiding prolonged heat exposure, and using a laptop stand rather than placing computers on the lap are simple, zero-risk interventions for men with impaired spermatogenesis.
Supplements and Testosterone: What the Evidence Actually Shows
The supplement industry’s exploitation of men’s interest in testosterone optimization is aggressive and largely unsupported by clinical evidence. Understanding which interventions have actual evidence separates the useful from the wasteful — and the occasionally harmful.
Zinc: an essential mineral for testosterone synthesis and spermatogenesis. Zinc deficiency genuinely impairs both, and supplementation in zinc-deficient men can restore testosterone and improve semen parameters. A 1996 study in Nutrition (Prasad et al.) found zinc restriction substantially reduced testosterone in healthy men, and zinc supplementation in zinc-deficient elderly men brought testosterone to normal range. However, zinc supplementation in zinc-replete men doesn’t raise testosterone above normal and may not provide fertility benefits at all.
The relevant question is whether a man is actually zinc-deficient (common in strict vegans, men with malabsorptive conditions, excessive sweaters, men on proton pump inhibitors) rather than whether zinc supplementation in general boosts testosterone.
Vitamin D: vitamin D receptors are expressed in Leydig cells and Sertoli cells, and observational studies consistently show positive correlations between vitamin D levels and testosterone in men. A 2011 RCT published in Hormone and Metabolic Research found vitamin D supplementation (3,332 IU/day) for one year raised testosterone by approximately 25% in vitamin D-deficient men — a substantial effect.
However, this effect showed up in deficient men (25-OH vitamin D below 30 ng/mL); supplementation in vitamin D-replete men hasn’t shown the same testosterone benefit. Vitamin D testing and supplementation to normalize deficiency is a reasonable approach for hypogonadal men — the impact for those actually deficient can be clinically meaningful.
Ashwagandha (Withania somnifera): this adaptogenic herb has the most clinical trial evidence of any botanical supplement for testosterone and fertility. A 2019 RCT in Medicine (Lopresti et al.) found 600 mg/day ashwagandha root extract significantly increased testosterone (average increase approximately 15%), improved semen quality, and improved stress, fatigue, and overall wellbeing over twelve weeks in a mixed healthy/stressed population. A 2010 study specifically in infertile men found significant improvements in sperm count, motility, and morphology with ashwagandha supplementation.
The proposed mechanisms involve cortisol reduction (ashwagandha reduces cortisol in multiple trials, and cortisol suppresses testosterone) and direct effects on Leydig cell steroidogenesis. The evidence for ashwagandha is stronger than for most testosterone-related supplements, though the absolute testosterone increases stay modest.
Fenugreek: several small trials have shown modest testosterone increases with fenugreek supplementation, thought to be mediated by inhibition of 5-alpha reductase and aromatase, which reduces conversion of testosterone to DHT and estradiol respectively. A 2011 study in Phytotherapy Research found 500 mg/day fenugreek extract for twelve weeks raised testosterone slightly and improved sexual function scores. Modest effect size, limited quality of evidence, but fenugreek appears to carry a reasonable safety profile.
The product David was taking — the supplement marketed for men’s health — actually contained fenugreek along with other compounds, but in a formulation that apparently had enough aromatase inhibitor activity to suppress his testosterone-to-estradiol ratio in a way that ultimately impaired his HPT axis function. The details matter. Not every herbal supplement effect works in the direction the label implies.
When to Seek Specialist Care: Male Fertility and Endocrinology
For infertility specifically: if semen analysis shows significant abnormalities (severe oligospermia, azoospermia, markedly abnormal morphology), referral to a reproductive urologist or male fertility specialist is appropriate. Azoospermia (no sperm in the ejaculate) can be obstructive (vas deferens blockage — surgically correctable) or non-obstructive (primary testicular failure — may still have microscopic testicular sperm extraction possible for IVF).
Distinguishing these requires hormonal evaluation (FSH levels in azoospermia: high FSH suggests testicular failure, normal FSH suggests possible obstruction) and potentially scrotal ultrasound and genetic testing. This evaluation should happen before any treatment decisions get made.
For testosterone specifically: men with testosterone below 200 ng/dL, men with significantly elevated LH (suggesting primary hypogonadism requiring understanding of the underlying cause), men with hypogonadism combined with other pituitary symptoms (headaches, visual disturbances, elevated prolactin — suggesting pituitary tumor requiring imaging), and men interested in preserving fertility while addressing hypogonadism should all be evaluated by an endocrinologist or reproductive urologist rather than managed empirically by primary care alone.
David’s situation resolved reasonably well. After stopping the supplement, working with a reproductive urologist, and using hCG to stimulate both endogenous testosterone and spermatogenesis, his hormonal parameters normalized over six months. His wife conceived naturally approximately eight months after the changes. The irony that his attempt to optimize his health had been the source of the problem wasn’t lost on him. The supplement had been expensive, confidently marketed, and genuinely harmful for his specific situation.
The lesson he took away — verify claims with actual evidence before making health decisions — applies well beyond the supplement aisle.
Hormonal Axis Testosterone Q&A About Testosterone and Male Fertility
Exogenous testosterone (injections, gels, or other replacement formulations) suppresses spermatogenesis in the large majority of men who use it, often to the point of azoospermia (no sperm), because it suppresses FSH through negative feedback on the pituitary. This effect is generally reversible after stopping testosterone in most men, though recovery may take six to eighteen months and isn’t guaranteed in every case.
Men who wish to father children should not start testosterone therapy without discussing fertility implications with a specialist and exploring fertility-preserving alternatives like hCG, clomiphene, or FSH therapy. Men already on testosterone therapy who want to conceive should work with a reproductive urologist to build a recovery plan.
How do I know if my testosterone is genuinely low?
A proper diagnosis of hypogonadism requires: (1) symptoms consistent with testosterone deficiency (reduced libido, erectile dysfunction, reduced energy, mood changes, loss of muscle mass, reduced bone density, increased fat mass, reduced body hair), AND (2) laboratory confirmation with total testosterone below established thresholds on at least two separate morning measurements (testosterone is highest in the morning and has natural day-to-day variability). A single borderline result without symptoms, or symptoms alone without lab confirmation, isn’t sufficient for a hypogonadism diagnosis.
Free testosterone measurement adds useful information when total testosterone is borderline and SHBG may be elevated. Normal total testosterone ranges vary by laboratory but typically run 300-1,000 ng/dL; the AUA considers below 300 ng/dL as low.
Can diet improve sperm quality?
Yes, substantially. A 2017 systematic review in Human Reproduction Update found consistent associations between healthier dietary patterns and better semen quality across multiple prospective and intervention studies. Specific findings: Mediterranean diet adherence is associated with better sperm motility and morphology. Higher antioxidant intake (vitamins C and E, zinc, folate, selenium, CoQ10 — primarily from food) reduces sperm DNA fragmentation. Lower processed meat consumption is associated with better morphology. Omega-3 fatty acid intake is associated with better sperm morphology and motility.
Obesity-reducing dietary patterns improve testosterone and spermatogenesis together. Avoiding highly processed foods, trans fats, and sugar while emphasizing whole foods, vegetables, fruits, lean proteins, and healthy fats represents the most evidence-supported dietary approach for male fertility optimization.
What’s the difference between “testosterone boosters” and actual medical testosterone therapy?
Medical testosterone therapy directly replaces testosterone by introducing testosterone molecules into the body (via injection, gel, pellet, or other delivery system). Pharmaceutical testosterone, directly raising circulating levels. “Testosterone boosters” are typically botanical and nutritional supplements claiming to raise testosterone through indirect mechanisms — reducing aromatase activity, reducing SHBG, reducing cortisol, providing precursors for testosterone synthesis.
For most such products, the clinical trial evidence is weak or absent, and effect sizes even for products with some evidence (ashwagandha, zinc in deficient men, vitamin D in deficient men) are modest compared to medical testosterone therapy. The major advantage of testosterone boosters: they don’t suppress pituitary function and spermatogenesis. The major disadvantage: they’re unlikely to adequately treat confirmed clinical hypogonadism.
Is there a relationship between testosterone levels and heart disease risk?
The relationship between testosterone and cardiovascular health is more complex than the testosterone-suppression concerns of the 1990s suggested. Low testosterone is associated with metabolic syndrome, insulin resistance, and cardiovascular disease in multiple large prospective studies. The directionality is partially confounded — metabolic disease reduces testosterone, and low testosterone worsens metabolic disease, creating a bidirectional relationship rather than a clean cause and effect. TRT in hypogonadal men improves body composition (reduces fat, increases lean mass), improves insulin sensitivity, and reduces inflammatory markers — all cardiovascular positives.
The concern about exogenous testosterone and cardiovascular events has been substantially addressed by larger, more rigorous studies, including the TRAVERSE trial (2023, NEJM), which found that testosterone therapy did not increase cardiovascular events in hypogonadal men with cardiovascular disease or risk. The exception is very high testosterone levels (supraphysiological, as in anabolic steroid use), clearly associated with adverse cardiovascular effects including left ventricular hypertrophy, dyslipidemia, and increased clotting risk.
How does age affect male fertility?
Male fertility does decline with age, though more gradually than female fertility and without the sharp decline analogous to menopause. After age 40, sperm DNA fragmentation rates increase, sperm motility declines, sperm morphology worsens progressively. Testosterone levels decline roughly 1-2% per year from the thirties onward, affecting both libido and supporting Sertoli cell function.
While men can father children into their fifties, sixties, and even beyond, paternal age is associated with increased rates of de novo genetic mutations (new mutations not inherited from either parent) in children, with some studies linking advanced paternal age to modestly increased risks of autism spectrum disorder, schizophrenia, and other conditions in offspring.
The absolute risk increase per year of paternal age is very small, but it’s a legitimate consideration in the fertility conversation — one rarely discussed with the same urgency as maternal age factors.
Sperm DNA Fragmentation: The Hidden Fertility Factor
Standard semen analysis — measuring sperm count, motility, and morphology — captures only part of the male fertility picture. Sperm DNA fragmentation is a dimension of sperm quality that standard analysis misses entirely, yet it carries significant implications for fertility outcomes that men and their reproductive partners deserve to understand.
Sperm DNA fragmentation refers to single or double-strand breaks in sperm DNA that occur either during sperm production (intrinsic fragmentation from apoptotic processes) or after sperm production (extrinsic fragmentation from oxidative stress in the reproductive tract and in semen). The rate is measured by specialized assays — the TUNEL assay, the COMET assay, or the sperm chromatin structure assay (SCSA) — and reported as the percentage of sperm with fragmented DNA.
Elevated DNA fragmentation (above roughly 15-25% depending on the assay) is associated with reduced natural conception rates, reduced IUI success rates, reduced IVF success rates, and increased miscarriage rates — even in men with normal sperm count, motility, and morphology on standard analysis. The mechanism: highly fragmented DNA, even in motile sperm capable of reaching and fertilizing an egg, impairs early embryo development and increases the risk of chromosomal abnormalities and implantation failure.
Oxidative stress is the primary driver of extrinsic DNA fragmentation, and this is where lifestyle and dietary interventions become specifically relevant.
Sources of oxidative stress that damage sperm DNA include: cigarette smoking (dramatically increases ROS in seminal plasma), varicocele (dilated veins in the scrotum that elevate scrotal temperature and create oxidative stress — the most common surgically correctable cause of elevated DNA fragmentation), infection and inflammation in the genital tract, leukocytospermia (white blood cells in semen from infection), obesity, and chronic psychological stress.
Antioxidant supplementation specifically targeting sperm DNA fragmentation has been tested in multiple clinical trials with generally positive results. A Cochrane review of antioxidant supplementation in male infertility found antioxidant combinations improving live birth rates compared to placebo in couples undergoing ART. The most commonly studied antioxidants: vitamin C (1,000-2,000 mg/day), vitamin E (400 IU/day), selenium (200 mcg/day), zinc (25-66 mg/day), CoQ10 (200-300 mg/day), lycopene (4-8 mg/day), L-carnitine (2-3g/day), and folate (400 mcg/day).
Combination formulations that include multiple antioxidants are available and may provide more consistent coverage than individual supplements. The evidence supports antioxidant supplementation for men with elevated DNA fragmentation and unexplained infertility, particularly those with identified oxidative stress risk factors.
The testing question: should DNA fragmentation testing be routine in male fertility evaluation? Most reproductive urologists recommend it in specific contexts: couples with unexplained infertility, recurrent pregnancy loss, failed IVF cycles despite normal female evaluation, and men with the known risk factors listed above. Not universally covered by insurance, but its cost is modest relative to the expense of IVF cycles that might fail due to unrecognized high fragmentation.
The result directly informs treatment decisions — men with elevated fragmentation benefit from addressing the underlying cause (varicocele repair, infection treatment, antioxidants, lifestyle changes) before or alongside ART rather than proceeding straight to more aggressive ART.
Understanding Azoospermia: When No Sperm Are Found
Azoospermia — the complete absence of sperm in the ejaculate — is the most severe finding on semen analysis and affects roughly 1% of all men and 10-15% of infertile men. A condition that can produce real hopelessness in affected men, but modern reproductive technology offers paths to biological fatherhood for many men with azoospermia, and understanding the distinction between its two major forms is essential for appropriate counseling and treatment planning.
Obstructive azoospermia (OA) occurs when sperm production is normal but anatomical obstruction prevents sperm from reaching the ejaculate. Causes include prior vasectomy (the most common cause of OA in developed countries), bilateral absence of the vas deferens (CBAVD — associated with cystic fibrosis gene mutations), epididymal obstruction from prior infection (chlamydia, gonorrhea, tuberculosis), and iatrogenic injury from inguinal or scrotal surgery. The diagnostic clue is normal or near-normal FSH (indicating normal testicular function) combined with absence of sperm.
Testicular sperm extraction (TESE) can retrieve sperm from the testes for IVF with ICSI (intracytoplasmic sperm injection) in virtually all men with OA, with high success rates. Vasovasostomy (vasectomy reversal) and epididymovasostomy (bypassing epididymal obstruction) are microsurgical options that can restore natural fertility in selected OA cases.
Non-obstructive azoospermia (NOA) involves impaired or absent sperm production in the testes themselves. Causes include Klinefelter syndrome (47,XXY), Y chromosome AZF deletions, chemotherapy or radiation damage, severe primary testicular failure, and cryptorchidism-related testicular damage. Elevated FSH is the diagnostic marker — the pituitary “screaming louder” because the testes aren’t responding adequately.
The prognosis for finding usable sperm is less certain than in OA, but microdissection TESE (micro-TESE) — which uses microscopy to identify and extract the rare areas of residual sperm production in otherwise failure-predominant testes — can find sperm in roughly 50% of NOA cases, offering many men a path to biological fatherhood through IVF/ICSI that they might otherwise have believed was closed to them entirely.
References